Calcitonin controls bone formation by inhibiting the release of sphingosine 1-phosphate from osteoclasts

Nature Communications

Volumn 5, Issue , 2014, Pages

  Keller, Johannes ^a   Catala Lehnen, Philip ^a   Huebner, Antje K ^a,b   Jeschke, Anke ^a   Heckt, Timo ^a   Lueth, Anja ^c   Krause, Matthias ^a   Koehne, Till ^a   Albers, Joachim ^a   Schulze, Jochen ^a   Schilling, Sarah ^a   Haberland, Michael ^a   Denninger, Hannah ^a   Neven, Mona ^a   Hermans Borgmeyer, Irm ^a   Streichert, Thomas ^a   Breer, Stefan ^a   Barvencik, Florian ^a   Levkau, Bodo ^d   Rathkolb, Birgit ^e,f   Wolf, Eckhard ^e   Calzada Wack, Julia ^f   Neff, Frauke ^f   Gailus Durner, Valerie ^f   Fuchs, Helmut ^f   De Angelis, Martin Hrabě ^f,g,h   Klutmann, Susanne ^a   Tsourdi, Elena ⁱ   Hofbauer, Lorenz C ⁱ   Kleuser, Burkhard ^c   Chun, Jerold ^j   Schinke, Thorsten ^a   Amling, Michael ^a   more..

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b JENA UNIVERSITY HOSPITAL   (Germany)

^c UNIVERSITY OF POTSDAM   (Germany)

^d UNIVERSITY HOSPITAL ESSEN   (Germany)

^e UNIVERSITY OF MUNICH   (Germany)

^f INSTITUTE OF EPIDEMIOLOGY   (Germany)

^g TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^h GERMAN CENTER FOR DIABETES RESEARCH DZD   (Germany)

ⁱ UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^j SCRIPPS RESEARCH INSTITUTE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CALCITONIN; CALCITONIN RECEPTOR; FINGOLIMOD; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; SPHINGOSINE 1 PHOSPHATE; SPHINGOSINE 1 PHOSPHATE RECEPTOR; COLLAGENASE; LYSOPHOSPHOLIPID; SPHINGOSINE; SPHINGOSINE 1-PHOSPHATE;

AMINO ACID; BONE; HORMONE; INHIBITOR; LIPID; OSTEOLOGY; RODENT; SKELETON;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BACKCROSSING; BINDING SITE; BONE MARROW CELL; BONE MASS; BONE REMODELING; CELL CULTURE; CELL DIFFERENTIATION; CONTROLLED STUDY; EMBRYO; EMBRYONIC STEM CELL; GENE EXPRESSION; HYPOTHALAMUS; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; MOUSE; NONHUMAN; OSSIFICATION; OSTEOBLAST; OSTEOCLAST; OSTEOCLASTOGENESIS; OSTEOLYSIS; PHENOTYPE; SIGNAL TRANSDUCTION; TRABECULAR BONE; ALLELE; ANALOGS AND DERIVATIVES; ANIMAL; BONE; BONE DEVELOPMENT; C57BL MOUSE; CROSS BREEDING; CYTOLOGY; FEMALE; METABOLISM; OSTEOPOROSIS; PATHOPHYSIOLOGY; POROSITY; TRANSGENIC MOUSE;

MURINAE; MUS;

ALLELES; ANIMALS; BONE AND BONES; CALCITONIN; COLLAGENASES; CROSSES, GENETIC; FEMALE; LYSOPHOSPHOLIPIDS; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; OSTEOBLASTS; OSTEOCLASTS; OSTEOGENESIS; OSTEOPOROSIS; PHENOTYPE; POROSITY; RECEPTORS, CALCITONIN; SIGNAL TRANSDUCTION; SPHINGOSINE;

EID: 84921744345     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms6215     Document Type: Article

References (63)

1. Zaidi, M. Skeletal remodeling in health and disease. Nat. Med. 13, 791-801 (2007).
2. Rachner, T. D., Khosla, S. & Hofbauer, L. C. Osteoporosis: now and the future. Lancet 377, 1276-1287 (2011).
3. Copp, D. H. & Cheney, B. Calcitonin-a hormone from the parathyroid which lowers the calcium-level of the blood. Nature 193, 381-382 (1962).
4. Foster, G. V. et al. Thyroid origin of calcitonin. Nature 202, 1303-1305 (1964).
5. Becker, K. L., Snider, R. & Nylen, E. S. Procalcitonin in sepsis and systemic inflammation: a harmful biomarker and a therapeutic target. Br. J. Pharmacol. 159, 253-264 (2010).
6. Lichtenstern, C., Brenner, T., Bardenheuer, H. J. & Weigand, M. A. Predictors of survival in sepsis: what is the best inflammatory marker to measure? Curr. Opin. Infect. Dis. 25, 328-336 (2012).
7. Christopoulos, G. et al. Comparative distribution of receptors for amylin and the related peptides calcitonin gene related peptide and calcitonin in rat and monkey brain. Can. J. Physiol. Pharmacol. 73, 1037-1041 (1995).
8. Marx, S. J., Woodward, C. J. & Aurbach, G. D. Calcitonin receptors of kidney and bone. Science 178, 999-1001 (1972).
9. Chambers, T. J. & Moore, A. The sensitivity of isolated osteoclasts to morphological transformation by calcitonin. J. Clin. Endocrinol. Metab. 57, 819-824 (1983).
10. Zaidi, M., Moonga, B. S. & Abe, E. Calcitonin and bone formation: a knockout full of surprises. J. Clin. Invest. 110, 1769-1771 (2002).
11. Davey, R. A. & Findlay, D. M. Calcitonin: physiology or fantasy? J. Bone Miner. Res. 28, 973-979 (2013).
12. Hirsch, P. F., Lester, G. E. & Talmage, R. V. Calcitonin, an enigmatic hormone: does it have a function? J. Musculoskelet. Neuronal Interact. 1, 299-305 (2001).
13. Hurley, D. L., Tiegs, R. D., Wahner, H. W. & Heath, 3rd H. Axial and appendicular bone mineral density in patients with long-term deficiency or excess of calcitonin. N. Engl. J. Med. 317, 537-541 (1987).
14. Hoff, A. O. et al. Increased bone mass is an unexpected phenotype associated with deletion of the calcitonin gene. J. Clin. Invest. 110, 1849-1857 (2002).
15. Huebner, A. K. et al. Calcitonin deficiency in mice progressively results in high bone turnover. J. Bone Miner. Res. 21, 1924-1934 (2006).
16. Schinke, T. et al. Decreased bone formation and osteopenia in mice lacking alpha-calcitonin gene-related peptide. J. Bone Miner. Res. 19, 2049-2056 (2004).
17. Lotinun, S. et al. Osteoclast-specific cathepsin K deletion stimulates S1P-dependent bone formation. J. Clin. Invest. 123, 666-681 (2013).
18. Pederson, L., Ruan, M., Westendorf, J. J., Khosla, S. & Oursler, M. J. Regulation of bone formation by osteoclasts involves Wnt/BMP signaling and the chemokine sphingosine-1-phosphate. Proc. Natl Acad. Sci. USA 105, 20764-20769 (2008).
19. Dacquin, R. et al. Amylin inhibits bone resorption while the calcitonin receptor controls bone formation in vivo. J. Cell Biol. 164, 509-514 (2004).
20. Schwenk, F., Baron, U. & Rajewsky, K. A cre-transgenic mouse strain for the ubiquitous deletion of loxP-flanked gene segments including deletion in germ cells. Nucleic Acids Res. 23, 5080-5081 (1995).
21. Sexton, P. M. et al. Procalcitonin has bioactivity at calcitonin receptor family complexes: potential mediator implications in sepsis. Crit. Care Med. 36, 1637-1640 (2008).
22. Casanova, E. et al. A CamKIIalpha iCre BAC allows brain-specific gene inactivation. Genesis 31, 37-42 (2001).
23. Clausen, B. E., Burkhardt, C., Reith, W., Renkawitz, R. & Förster, I. Conditional gene targeting in macrophages and granulocytes using LysMcre mice. Transgenic Res. 8, 265-277 (1999).
24. Rauch, A. et al. Glucocorticoids suppress bone formation by attenuating osteoblast differentiation via the monomeric glucocorticoid receptor. Cell Metab. 11, 517-531 (2010).
25. Wada, S., Udagawa, N., Nagata, N., Martin, T. J. & Findlay, D. M. Physiological levels of calcitonin regulate the mouse osteoclast calcitonin receptor by a protein kinase Alpha-mediated mechanism. Endocrinology 137, 312-320 (1996).
26. Yang, M. & Kream, B. E. Calcitonin induces expression of the inducible cAMP early repressor in osteoclasts. Endocrine 33, 245-253 (2008).
27. Hisano, Y., Kobayashi, N., Kawahara, A., Yamaguchi, A. & Nishi, T. The sphingosine 1-phosphate transporter, SPNS2, functions as a transporter of the phosphorylated form of the immunomodulating agent FTY720. J. Biol. Chem. 286, 1758-1766 (2011).
28. Kawahara, A. et al. The sphingolipid transporter spns2 functions in migration of zebrafish myocardial precursors. Science 323, 524-527 (2009).
29. Ryu, J. et al. Sphingosine 1-phosphate as a regulator of osteoclast differentiation and osteoclast-osteoblast coupling. EMBO J. 25, 5840-5851 (2006).
30. Chakraborty, M., Chatterjee, D., Kellokumpu, S., Rasmussen, H. & Baron, R. Cell cycle-dependent coupling of the calcitonin receptor to different G proteins. Science 251, 1078-1082 (1991).
31. Force, T. et al. A cloned porcine renal calcitonin receptor couples to adenylyl cyclase and phospholipase C. Am. J. Physiol. 262, F1110-F1115 (1992).
32. Chun, J., Hla, T., Lynch, K. R., Spiegel, S. & Moolenaar, W. H. International Union of Basic and Clinical Pharmacology. LXXVIII. Lysophospholipid receptor nomenclature. Pharmacol. Rev. 62, 579-587 (2010).
33. Mutoh, T., Rivera, R. & Chun, J. Insights into the pharmacological relevance of lysophospholipid receptors. Br. J. Pharmacol. 165, 829-844 (2012).
34. Allende, M. L., Yamashita, T. & Proia, R. L. G-protein-coupled receptor S1P1 acts within endothelial cells to regulate vascular maturation. Blood 102, 3665-3667 (2003).
35. Ishii, I. et al. Selective loss of sphingosine 1-phosphate signaling with no obvious phenotypic abnormality in mice lacking its G protein-coupled receptor, LP(B3)/EDG-3. J. Biol. Chem. 276, 33697-33704 (2001).
36. Aubin, I. et al. A deletion in the gene encoding sphingomyelin phosphodiesterase 3 (Smpd3) results in osteogenesis and dentinogenesis imperfecta in the mouse. Nat. Genet. 37, 803-805 (2005).
37. Glorieux, F. H. Osteogenesis imperfecta. Best Pract. Res. Clin. Rheumatol. 22, 85-100 (2008).
38. Khavandgar, Z. et al. A cell-autonomous requirement for neutral sphingomyelinase 2 in bone mineralization. J. Cell Biol. 194, 277-289 (2011).
39. Vogel, P. et al. Incomplete inhibition of sphingosine 1-phosphate lyase modulates immune system function yet prevents early lethality and non-lymphoid lesions. PLoS ONE 4, e4112 (2009).
40. Ishii, M. et al. Sphingosine-1-phosphate mobilizes osteoclast precursors and regulates bone homeostasis. Nature 458, 524-528 (2009).
41. Potts, J. T. & Gardella, T. J. Progress, paradox, and potential: parathyroid hormone research over five decades. Ann. N. Y. Acad. Sci. 1117, 196-208 (2007).
42. Overington, J. P., Al-Lazikani, B. & Hopkins, A. L. How many drug targets are there? Nat. Rev. Drug Discov. 5, 993-996 (2006).
43. Huebner, A. K. et al. The role of calcitonin and alpha-calcitonin gene-related peptide in bone formation. Arch. Biochem. Biophys. 473, 210-217 (2008).
44. Davey, R. A. et al. Calcitonin receptor plays a physiological role to protect against hypercalcemia in mice. J. Bone Miner. Res. 23, 1182-1193 (2008).
45. Fiering, S. et al. Targeted deletion of 5'HS2 of the murine beta-globin LCR reveals that it is not essential for proper regulation of the beta-globin locus. Genes Dev. 9, 2203-2213 (1995).
46. Olson, E. N., Arnold, H. H., Rigby, P. W. & Wold, B. J. Know your neighbors: three phenotypes in null mutants of the myogenic bHLH gene MRF4. Cell 85, 1-4 (1996).
47. Scacheri, P. C. et al. Bidirectional transcriptional activity of PGK-neomycin and unexpected embryonic lethality in heterozygote chimeric knockout mice. Genesis 30, 259-263 (2001).
48. Gooi, J. H. et al. Calcitonin impairs the anabolic effect of PTH in young rats and stimulates expression of sclerostin by osteocytes. Bone 46, 1486-1497 (2010).
49. Boyce, B. F. & Xing, L. Osteoclasts, no longer osteoblast slaves. Nat. Med. 12, 1356-1358 (2006).
50. Martin, T., Gooi, J. H. & Sims, N. A. Molecular mechanisms in coupling of bone formation to resorption. Crit. Rev. Eukaryot. Gene Expr. 19, 73-88 (2009).
51. Segovia-Silvestre, T. et al. Advances in osteoclast biology resulting from the study of osteopetrotic mutations. Hum. Genet. 124, 561-577 (2009).
52. Seitz, S. et al. Paget's disease of bone: histologic analysis of 754 patients. J. Bone Miner. Res. 24, 62-69 (2009).
53. Negishi-Koga, T. et al. Suppression of bone formation by osteoclastic expression of semaphorin 4D. Nat. Med. 17, 1473-1480 (2011).
54. Zhao, C. et al. Bidirectional ephrinB2-EphB4 signaling controls bone homeostasis. Cell Metab. 4, 111-121 (2006).
55. Fukuhara, S. et al. The sphingosine-1-phosphate transporter Spns2 expressed on endothelial cells regulates lymphocyte trafficking in mice. J. Clin. Invest. 122, 1416-1426 (2012).
56. Brinkmann, V. et al. Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis. Nat. Rev. Drug Discov. 9, 883-897 (2010).
57. Chun, J. & Hartung, H. P. Mechanism of action of oral fingolimod (FTY720) in multiple sclerosis. Clin. Neuropharmacol. 33, 91-101 (2010).
58. Lu, J. T. et al. Mice lacking alpha-calcitonin gene-related peptide exhibit normal cardiovascular regulation and neuromuscular development. Mol. Cell. Neurosci. 14, 99-120 (1999).
59. Schulze, J. et al. Interleukin-33 is expressed in differentiated osteoblasts and blocks osteoclast formation from bone marrow precursor cells. J. Bone Miner. Res. 26, 704-717 (2011).
60. Fuchs, H. et al. Mouse phenotyping. Methods 53, 120-135 (2011).
61. Nieuwenhuis, B. et al. Involvement of the ABC-transporter ABCC1 and the sphingosine 1-phosphate receptor subtype S1P(3) in the cytoprotection of human fibroblasts by the glucocorticoid dexamethasone. J. Mol. Med. 87, 645-657 (2009).
62. Albers, J. et al. Canonical Wnt signaling inhibits osteoclastogenesis independent of osteoprotegerin. J. Cell Biol. 200, 537-549 (2013).
63. Parfitt, A. M. et al. Bone histomorphometry: standardization of nomenclature, symbols, and units. Report of the ASBMR Histomorphometry Nomenclature Committee. J. Bone Miner. Res. 2, 595-610 (1987).